MariMed Believes Strong Brands Win Long Term Growth
In our latest TDR Trade To Black podcast, host Shadd Dales sits down with the leadership team at MariMed (CSE: MRMD / OTCQX: MRMD) following another strong earnings report that continues to separate the company from a lot of operators in the cannabis sector right now. CEO Jon Levine and CFO Mario Pinho break down the company’s latest quarter, including $39.5 million in revenue, 44% adjusted EBITDA growth, expanding margins, and why MariMed continues focusing on disciplined growth instead of chasing scale just for headlines.
The conversation also dives into the impact of cannabis rescheduling, the removal of 280E taxes on the medical side, expansion opportunities in New York, Ohio, Massachusetts, and Delaware, plus why brands like Betty’s Eddies continue gaining market share across multiple states. Shadd and the MariMed team also discuss the future of cannabis branding, consumer loyalty, operational discipline, wholesale growth, and why the next phase of the cannabis industry may finally reward companies that stayed financially responsible during the toughest years of the sector.
On the financial results, Dales framed the quarter less as a story about headline growth and more about the quality of that growth. Pinho walked through the primary drivers of margin expansion — mix optimization, deeper wholesale distribution, tighter inventory management, and disciplined SG&A — emphasizing that none of it was the result of a one-time event. EBITDA margins expanded from seven to nine percent, and GAAP losses continued to narrow.
Wholesale strength was a notable highlight, with MariMed’s brands, particularly Betty’s Eddies, maintaining or growing market share even as retail softened due to more price-conscious consumer behavior. Levine credited years of cultivation and manufacturing consistency, along with an active brand ambassador program that educates budtenders directly in-store, as the key to holding share while competitors lost ground.
The company’s preferred stock restructuring also drew attention, with Pinho explaining that eliminating a near-term mandatory conversion and extending maturities to an average of 4.6 years significantly reduces dilution risk and gives the company greater strategic flexibility heading into a more favorable regulatory environment. With 280E relief now arriving on the medical side, capital previously consumed by taxes can be redeployed into expansion in markets like New York, Ohio, and potentially Massachusetts.
With federal momentum building, 280E relief beginning to take shape, and more operators preparing for the next stage of legalization, this was one of the more important conversations we’ve had this earnings season.
